Tarsus Pharmaceuticals Inc [TARS] stock is trading at $44.63, down -6.02%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TARS shares have lost -8.77% over the last week, with a monthly amount glided 0.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tarsus Pharmaceuticals Inc [NASDAQ: TARS] stock has seen the most recent analyst activity on November 20, 2023, when Goldman initiated its Neutral rating and assigned the stock a price target of $19. Previously, William Blair started tracking the stock with Outperform rating on July 18, 2023, and set its price target to $44. On May 18, 2023, Guggenheim initiated with a Buy rating. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $40 on August 01, 2022. H.C. Wainwright initiated its recommendation with a Buy and recommended $40 as its price target on December 21, 2021. Oppenheimer started tracking with a Outperform rating for this stock on November 23, 2021, and assigned it a price target of $55. In a note dated November 10, 2020, Raymond James initiated an Strong Buy rating and provided a target price of $39 on this stock.
Tarsus Pharmaceuticals Inc [TARS] stock has fluctuated between $20.08 and $57.28 over the past year. Currently, Wall Street analysts expect the stock to reach $64 within the next 12 months. Tarsus Pharmaceuticals Inc [NASDAQ: TARS] shares were valued at $44.63 at the most recent close of the market. An investor can expect a potential return of 43.4% based on the average TARS price forecast.
Analyzing the TARS fundamentals
Tarsus Pharmaceuticals Inc [NASDAQ:TARS] reported sales of 182.95M for the trailing twelve months, which represents a growth of 407.86%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.66%, Pretax Profit Margin comes in at -0.63%, and Net Profit Margin reading is -0.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.47 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.43 points at the first support level, and at 40.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 47.92, and for the 2nd resistance point, it is at 51.21.
Ratios To Look Out For
For context, Tarsus Pharmaceuticals Inc’s Current Ratio is 4.42. As well, the Quick Ratio is 4.39, while the Cash Ratio is 1.18. Considering the valuation of this stock, the price to sales ratio is 10.15, the price to book ratio is 7.62.
Transactions by insiders
Recent insider trading involved Azamian Bobak R., President/CEO and Board Chair, that happened on Mar 24 ’25 when 6000.0 shares were sold. Officer, Azamian Bobak R. completed a deal on Mar 24 ’25 to buy 6000.0 shares. Meanwhile, Chief Commercial Officer Mottiwala Aziz sold 3643.0 shares on Mar 18 ’25.
